HOUSTON, April 27, 2021 /PRNewswire/ -- Marker
Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications, today
announced that it will present data detailing a new robotics
technology to aid in multi-tumor-associated antigen (mTAA)-specific
T cell therapy manufacturing at the upcoming American Society of
Gene & Cell Therapy (ASGCT) Annual Meeting, taking place
virtually May 11-14, 2021. The
data will be presented by lead author Anastasiya Smith, Ph.D.
The presentation details how the robotic assistant prototype,
co-designed by Marker Therapeutics and ABB Robotics, could in the
future be integrated in a standard biosafety cabinet to collaborate
with a human operator during mTAA-specific T cell manufacturing.
The researchers found that the robotic assistant prototype was more
precise and accurate than human operators in pipetting liquid and
was more consistent in the number of cycles performed over a 1-hour
test period, while the human operator's performance deteriorated
over time. The authors conclude that the future combination of
process simplification with robotic automation may be able to
address some of the challenges associated with cell therapy and
make this therapy readily available to a larger patient
population.
Presentation Details
Title: "Robotic Automation of T Cell Generation for
the Treatment of Acute Myeloid Leukemia (AML)"
Authors: Anastasiya Smith,
Ph.D., et al.
Session Type: Digital Poster Presentation
Session Date/Time: Tuesday, May 11,
2021, 8:00 a.m. - 10:00 a.m.
ET
Session Title: Cell Therapies
Abstract: 772
The abstract is available on ASGCT's website and in an online
supplement to the ASGCT journal. The poster presentation will be
available to ASGCT registrants beginning May
11, 2021.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology
company specializing in the development of next-generation T
cell-based immunotherapies for the treatment of hematological
malignancies and solid tumor indications. Marker's cell therapy
technology is based on the selective expansion of non-engineered,
tumor-specific T cells that recognize tumor associated antigens
(i.e. tumor targets) and kill tumor cells expressing those targets.
This population of T cells is designed to attack multiple tumor
targets following infusion into patients and to activate the
patient's immune system to produce broad spectrum anti-tumor
activity. Because Marker does not genetically engineer its T cell
therapies, we believe that our product candidates will be easier
and less expensive to manufacture, with reduced toxicities,
compared to current engineered CAR-T and TCR-based approaches, and
may provide patients with meaningful clinical benefit. As a result,
Marker believes its portfolio of T cell therapies has a compelling
product profile, as compared to current gene-modified CAR-T and
TCR-based therapies.
To receive future press releases via email, please
visit: https://www.markertherapeutics.com/email-alerts
View original content to download
multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-to-present-multi-tumor-associated-antigen-mtaa-specific-t-cell-manufacturing-robotics-data-at-the-2021-american-society-of-gene--cell-therapy-asgct-annual-meeting-301278520.html
SOURCE Marker Therapeutics, Inc.